Study of Anti-PD-1 Antibody SHR-1210 Plus Apatinib vs SHR-1210 as Second-Line Treatment of Advanced Esophageal Squamous Cell

Sponsor
Feng Wang
Study ID
NCT05049681
Phase
PHASE3
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Accepted

Interventions

  • Camrelizumab — DRUG
    SHR-1210（Camrelizumab） 200 mg，Intravenous injection， q2W ，A course of treatment need 28 days.
  • Apatinib — DRUG
    Apatinib 250mg, q.d.po

Study Details

The purpose of this study is to observe and evaluate the efficacy and safety of Anti-PD-1 antibody SHR-1210 plus apatinib versus SHR-1210 as second-line treatment of advanced esophageal squamous cell.

Key Dates

Start date
Dec 5, 2021
Status verified
Sep 2021
Primary completion
Dec 20, 2022
Completion
Jun 30, 2023

Study Design

Enrollment
234 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: SHR-1210（Camrelizumab）+Apatinib
    Apatinib 250mg, q.d.po; SHR-1210（Camrelizumab） 200 mg，Intravenous injection,q2W ,A course of treatment need 28 days.
  • Active Comparator: SHR-1210（Camrelizumab）
    SHR-1210（Camrelizumab） 200 mg，Intravenous injection. q2W ,A course of treatment need 28 days.

Primary Outcome Measure

Overall survival(OS) [ Time Frame: up to 2 year ]

Central Contacts

Related Studies